Hepatitis research and treatment最新文献_第7页

Expression of Hepatitis B Virus Surface Antigen Containing Y100C Variant Frequently Detected in Occult HBV Infection. 隐匿性HBV感染中常见的含Y100C变异的乙型肝炎病毒表面抗原的表达

Hepatitis research and treatment Pub Date : 2011-01-01 Epub Date: 2011-02-06 DOI: 10.1155/2011/695859

Francisco C A Mello, Nora Martel, Selma A Gomes, Natalia M Araujo

引用次数: 26

The role of liver fibrosis assessment in the management of patients with chronic hepatitis B infection: lessons learned from a single centre experience. 肝纤维化评估在慢性乙型肝炎感染患者管理中的作用:来自单一中心经验的教训。

Hepatitis research and treatment Pub Date : 2011-01-01 Epub Date: 2011-10-30 DOI: 10.1155/2011/524027

Raza Malik, Patrick Kennedy, Deepak Suri, Ashley Brown, Rob Goldin, Janice Main, Howard Thomas, Mark Thursz

{"title":"The role of liver fibrosis assessment in the management of patients with chronic hepatitis B infection: lessons learned from a single centre experience.","authors":"Raza Malik, Patrick Kennedy, Deepak Suri, Ashley Brown, Rob Goldin, Janice Main, Howard Thomas, Mark Thursz","doi":"10.1155/2011/524027","DOIUrl":"https://doi.org/10.1155/2011/524027","url":null,"abstract":"Background & Aims. Assess the clinical utility of the Prati criteria and normal ALT (<40 IU/L) in a cohort of patients with chronic hepatitis B infection (CHB). Methods. Serology, radiology, and histology were obtained in 140 patients with CHB. Results. HBeAg(+) group: 7 patients (7/56-12% HBeAg(+) group) misclassified as \"immunotolerant\", with HBV DNA > 6 log copies/ml and normal ALT, who in fact had moderate/severe fibrosis on liver biopsy. HBeAg(-) group: 10 patients with normal ALT and moderate/severe fibrosis on liver biopsy; 4 of these patients had >3 log copies/ml HBV DNA levels and 6 patients misclassified as \"inactive carriers\" with negative HBV DNA levels normal ALT and moderate/severe fibrosis (6/84-7% HBeAg(-) group). Two male HBeAg(+) and three male HBeAg(-) patients with ALT between 20 and 30 IU/L and moderate/severe fibrosis on liver biopsy would have been further mischaracterised using the Prati criteria for normal ALT. Age and ethnic group were more important predictors of moderate/severe fibrosis in multivariate analysis. Conclusion. HBeAg status, age, ethnic origin with longitudinal assessment of LFTs and viral load should be studied in patients with \"normal ALT\" at the upper end of normal range (ALT 20-40 IU/L) to appropriately classify patients and identify patients for liver fibrosis assessment to inform treatment decisions.","PeriodicalId":73232,"journal":{"name":"Hepatitis research and treatment","volume":" ","pages":"524027"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/524027","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30136038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Validation of hepascore as a predictor of liver fibrosis in patients with chronic hepatitis C infection. hepascore作为慢性丙型肝炎感染患者肝纤维化预测因子的验证

Hepatitis research and treatment Pub Date : 2011-01-01 Epub Date: 2011-12-28 DOI: 10.1155/2011/972759

Hamid Kalantari, Hannan Hoseini, Anahita Babak, Majid Yaran

{"title":"Validation of hepascore as a predictor of liver fibrosis in patients with chronic hepatitis C infection.","authors":"Hamid Kalantari, Hannan Hoseini, Anahita Babak, Majid Yaran","doi":"10.1155/2011/972759","DOIUrl":"https://doi.org/10.1155/2011/972759","url":null,"abstract":"Introduction. Liver biopsy is an invasive determinator for hepatic fibrosis. Serum biomarkers can probably be used as an alternative to liver biopsy in assessment of the degree of fibrosis in patients with chronic Hepatitis C. Method. Eighty patients with chronic Hepatitis C were included in the study using simple nonrandom sampeling metod. After fulfillment of liver biopsy, the patients were categorized according to the METAVIR Scoring system. The Hepascore algorithm is computed based on age, sex, and the serum levels of total bilirubin, δ-glutamyl transferase, α2-Macroglobulin, and hyaluronic acid. The spearman and ROC tests were used. Results. According to the liver biopsy results, 12, 25, 20, 7 and 16 patients had F0, F1, F2, F3, and F4, respectively. With regard to the 0.34 cut-off point Hepascore had 67%, 56%, 64%, and 56% sensitivity, specificity, respectively, positive prediction value (PPV), and negative prediction value (NPV), respectively, for diagnosis of significant fibrosis. For a Hepascore cut-off point 0.61, sensitivity, specificity, respectively, PPV and NPB 82%, 86%, 70%, and 92% in diagnosis of severe fibrosis. For a Hepascore cut-off point 0.84, sensitivity, specificity, PPV and NPB were respectively 100%, 97%, 89%, and 100% for diagnosis of cirrhosis. Conclusion. Hepascore has a high value in diagnosis of the level of fibrosis, particularly cirrhosis. Therefore, it can be used for primary screening of patients to determine the need for liver biopsy.","PeriodicalId":73232,"journal":{"name":"Hepatitis research and treatment","volume":" ","pages":"972759"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/972759","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30393604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 21

Etiology and Viral Genotype in Patients with End-Stage Liver Diseases admitted to a Hepatology Unit in Colombia. 哥伦比亚肝病科收治的终末期肝病患者的病因和病毒基因型。

Hepatitis research and treatment Pub Date : 2011-01-01 Epub Date: 2011-09-20 DOI: 10.1155/2011/363205

Fabian Cortes-Mancera, Carmen Luisa Loureiro, Sergio Hoyos, Juan-Carlos Restrepo, Gonzalo Correa, Sergio Jaramillo, Helene Norder, Flor Helene Pujol, Maria-Cristina Navas

{"title":"Etiology and Viral Genotype in Patients with End-Stage Liver Diseases admitted to a Hepatology Unit in Colombia.","authors":"Fabian Cortes-Mancera, Carmen Luisa Loureiro, Sergio Hoyos, Juan-Carlos Restrepo, Gonzalo Correa, Sergio Jaramillo, Helene Norder, Flor Helene Pujol, Maria-Cristina Navas","doi":"10.1155/2011/363205","DOIUrl":"10.1155/2011/363205","url":null,"abstract":"Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the principal risk factor associated to end-stage liver diseases in the world. A study was carried out on end-stage liver disease cases admitted to an important hepatology unit in Medellin, the second largest city in Colombia. From 131 patients recruited in this prospective study, 71% of cases were diagnosed as cirrhosis, 12.2% as HCC, and 16.8% as cirrhosis and HCC. Regarding the risk factors of these patients, alcohol consumption was the most frequent (37.4%), followed by viral etiology (17.6%). Blood and/or hepatic tissue samples from patients with serological markers for HCV or HBV infection were characterized; on the basis of the phylogenetic analysis of HCV 5' UTR and HBV S gene, isolates belonged to HCV/1 and HBV/F3, respectively. These results confirm the presence of strains associated with poor clinical outcome, in patients with liver disease in Colombia; additionally, HBV basal core promoter double mutant was identified in HCC cases. Here we show the first study of cirrhosis and/or HCC in Colombian and HBV and HCV molecular characterization of these patients. Viral aetiology was not the main risk factor in this cohort but alcohol consumption.","PeriodicalId":73232,"journal":{"name":"Hepatitis research and treatment","volume":" ","pages":"363205"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3177233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30160404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of HBV Genetic Variability on RNAi Strategies. HBV遗传变异对RNAi策略的影响。

Hepatitis research and treatment Pub Date : 2011-01-01 Epub Date: 2011-07-02 DOI: 10.1155/2011/367908

Nattanan Panjaworayan, Chris M Brown

引用次数: 10

TP53 Mutations and HBX Status Analysis in Hepatocellular Carcinomas from Iran: Evidence for Lack of Association between HBV Genotype D and TP53 R249S Mutations. 伊朗肝细胞癌中TP53突变和HBX状态分析:HBV基因型D和TP53 R249S突变之间缺乏相关性的证据

Hepatitis research and treatment Pub Date : 2011-01-01 Epub Date: 2011-08-17 DOI: 10.1155/2011/475965

Behnoush Abedi-Ardekani, Doriane Gouas, Stephanie Villar, Masoud Sotoudeh, Pierre Hainaut

{"title":"TP53 Mutations and HBX Status Analysis in Hepatocellular Carcinomas from Iran: Evidence for Lack of Association between HBV Genotype D and TP53 R249S Mutations.","authors":"Behnoush Abedi-Ardekani, Doriane Gouas, Stephanie Villar, Masoud Sotoudeh, Pierre Hainaut","doi":"10.1155/2011/475965","DOIUrl":"https://doi.org/10.1155/2011/475965","url":null,"abstract":"High incidence of HCC is mostly due to the combination of two major risk factors, chronic infection with hepatitis B (HBV) and/or C (HCV) viruses and exposure to the mycotoxin aflatoxin B(1), which induces a particular mutation at codon 249 in TP53 (R249S). Eight genotypes of HBV are diversely found in high and low incidence areas. Regardless of documented strong associations between TP53 R249S mutation and HBV genotypes B, C, A or E, there is no report of such association for genotype D despite of the presence of aflatoxin in areas with high prevalence of HBV genotype D. In Iran, 3% of the population is chronically infected with HBV, predominantly genotype D. Twenty-one histologically confirmed HCC cases from Iran were analyzed for TP53 R249S and HBV double mutations 1762(T)/1764(A), hallmarks of more pathogenic forms of HBV. We did not detect any of these mutations. In addition, we report the only case identified so far carrying both R249S mutation and chronic HBV genotype D, a patient from The Gambia in West Africa. This paper suggests that association between HBV genotype D and aflatoxin-induced TP53 mutation is uncommon, explaining the relatively lower incidence of HCC in areas where genotype D is highly prevalent.","PeriodicalId":73232,"journal":{"name":"Hepatitis research and treatment","volume":" ","pages":"475965"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/475965","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30100912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Treatment of chronic hepatitis C virus infection in dialysis patients: an update. 透析患者慢性丙型肝炎病毒感染的治疗:最新进展

Hepatitis research and treatment Pub Date : 2010-01-01 Epub Date: 2010-09-20 DOI: 10.1155/2010/267412

Hugo Weclawiak, Nassim Kamar, Abdellatif Ould-Mohamed, Isabelle Cardeau-Desangles, Jacques Izopet, Lionel Rostaing

引用次数: 7

Long-term effects of antiviral therapy in patients with chronic hepatitis C. 慢性丙型肝炎患者抗病毒治疗的长期效果。

Hepatitis research and treatment Pub Date : 2010-01-01 Epub Date: 2010-09-27 DOI: 10.1155/2010/562578

Tatehiro Kagawa, Emmet B Keeffe

{"title":"Long-term effects of antiviral therapy in patients with chronic hepatitis C.","authors":"Tatehiro Kagawa, Emmet B Keeffe","doi":"10.1155/2010/562578","DOIUrl":"https://doi.org/10.1155/2010/562578","url":null,"abstract":"Chronic hepatitis C is a major cause of chronic liver disease globally, and the natural history of progression may lead to cirrhosis with liver failure, hepatocellular carcinoma, and premature liver-related death. Emerging data demonstrates that interferon-based therapy, particularly among those achieving a sustained virologic response (SVR), is associated with long-term persistence of SVR, improved fibrosis and inflammation scores, reduced incidence of hepatocellular carcinoma, and prolonged life expectancy. This reduction in the rate of progression has also been demonstrated in patients with chronic hepatitis C and cirrhosis in some but not all studies. The majority of these results are reported with standard interferon therapy, and long-term results of peginterferon plus ribavirin therapy with a higher likelihood of SVR should have a yet greater impact on the population of treated patients. The impact on slowing progression is greatest in patients with an SVR, less in relapsers, and equivocal in nonresponders. Thus, the natural history of chronic hepatitis C after completion of antiviral therapy is favorable with achievement of an SVR, although further data are needed to determine the likely incremental impact of peginterferon plus ribavirin, late long-term effects of therapy, and the benefit of treatment in patients with advanced hepatic fibrosis.","PeriodicalId":73232,"journal":{"name":"Hepatitis research and treatment","volume":"2010 ","pages":"562578"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2010/562578","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29561194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Optimal erythrocyte ribavirin level to reduce the risk of anemia and obtain an early virological response in patients with chronic hepatitis C caused by genotype 1b infection. 乙型基因型慢性丙型肝炎感染患者最佳红细胞利巴韦林水平降低贫血风险并获得早期病毒学应答

Hepatitis research and treatment Pub Date : 2010-01-01 Epub Date: 2010-09-08 DOI: 10.1155/2010/495928

Rie Kubota, Takako Komiyama, Naoki Kumagai, Miyuki Kimijima, Keiko Mitsuki, Junko Uetake, Fumihiko Kaneko, Satoshi Tsunematsu, Kanji Tsuchimoto

{"title":"Optimal erythrocyte ribavirin level to reduce the risk of anemia and obtain an early virological response in patients with chronic hepatitis C caused by genotype 1b infection.","authors":"Rie Kubota, Takako Komiyama, Naoki Kumagai, Miyuki Kimijima, Keiko Mitsuki, Junko Uetake, Fumihiko Kaneko, Satoshi Tsunematsu, Kanji Tsuchimoto","doi":"10.1155/2010/495928","DOIUrl":"https://doi.org/10.1155/2010/495928","url":null,"abstract":"Aims. To determine whether the erythrocyte phosphorylated ribavirin (RBV) level might be a useful index of EVR and risk of anemia and to determine the optimal dose of RBV in 24 patients with hepatitis C with pegylated interferon and RBV. Methodology. The RBV level was measured by a high-performance liquid chromatography. Results and Conclusion. In patients aged 50 years or over, a negative correlation (r = -0.548, P < .05) was observed between the RBV level at week 2 and rate of Hb reduction (ΔHb) at week 4. The ΔHb at week 4 was significantly greater in patients with RBV levels of ≥800 μM (-25.5 ± 10.1%) than in patients with RBV levels <800 μM (-15.6 ± 7.7%). None of the patients with RBV levels <600 μM at week 2 achieved EVR and SVR. Thus the optimal levels of erythrocyte phosphorylated RBV at week 2 of therapy in order to achieve EVR without anemia seemed to be 600-800 μM.","PeriodicalId":73232,"journal":{"name":"Hepatitis research and treatment","volume":"2010 ","pages":"495928"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2010/495928","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29531078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Tumor necrosis factor receptor 1 expression is upregulated in dendritic cells in patients with chronic HCV who respond to therapy. 对治疗有反应的慢性HCV患者树突状细胞中肿瘤坏死因子受体1表达上调。

Hepatitis research and treatment Pub Date : 2010-01-01 Epub Date: 2010-08-03 DOI: 10.1155/2010/429243

Raul Cubillas, Katherine Kintner, Frances Phillips, Nitin J Karandikar, Dwain L Thiele, Geri R Brown

{"title":"Tumor necrosis factor receptor 1 expression is upregulated in dendritic cells in patients with chronic HCV who respond to therapy.","authors":"Raul Cubillas, Katherine Kintner, Frances Phillips, Nitin J Karandikar, Dwain L Thiele, Geri R Brown","doi":"10.1155/2010/429243","DOIUrl":"https://doi.org/10.1155/2010/429243","url":null,"abstract":"The present studies assessed the level of tumor necrosis factor receptor (TNFR) expression in peripheral blood mononuclear cells (PBMCs) subsets from patients with chronic HCV undergoing interferon α/ribavirin-based therapy (Ifn/R). Methods. TNFR family member mRNA expression was determined using quantitative real-time PCR assays (RTPCRs) in PBMC from 39 HCV+ patients and 21 control HCV- patients. Further subset analysis of HCV + patients (untreated (U), sustained virological responders (SVR), and nonresponders (NR)/relapsers (Rel)) PBMC was performed via staining with anti-CD123, anti-CD33, anti-TNFR1 or via RTPCR for TNFR1 mRNA. Results. A similar level of TNFR1 mRNA in PBMC from untreated HCV+ genotype 1 patients and controls was noted. TNFR1 and TNFR2 mRNA levels in PBMC from HCV+ patients with SVR were statistically different than levels in HCV(-) patients. A significant difference was noted between the peak values of TNFR1 of the CD123+ PBMC isolated from SVR and the NR/Rel. Conclusion. Upregulation of TNFR1 expression, occurring in a specific subset of CD123+ dendritic cells, appeared in HCV+ patients with SVR.","PeriodicalId":73232,"journal":{"name":"Hepatitis research and treatment","volume":"2010 ","pages":"429243"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2010/429243","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29531618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11